Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:Today's ATE Announcement was a Zero News Event

[Benedictus]

davgro wrote: Today's anouncement of Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic (PK/PD) study of otenaproxesul's faster-absorbing formulation for acute pain was anticipated by investors thus no significant movement in the share price or unusual trading volume (i.e. accumulation).  In fact there has been more selling of shares at the bid then purchases at the ask.

It is still wait and see as no significant news will occur until calendar Q1 2024.  I would not be surprised to see the stock move lower towards the 52-week low with current market/economic conditions and tax loss selling season approaching.  In summary, there is no rush to purchase shares as they may be had for less as 2023 comes to an end.

A quick look at the 5 year price chart for ATE tells the true story.  Since the August 2021 price drop daily trading volume has decreased significantly and the share price is a 3-year almost straight line decline.

[img]https://www.stockwatch.com/Chart/Hist?symbol=ATE®ion=C&d1=20180929&d2=20230928&per=d&npdivs=20&width=830&priceheight=400&ptype=bar&indheight=100&log=F&dplus=0&ind1=vol&ind2=none&ind3=none&ind1p1=12&ind1p2=25&ind1p3=50&ind2p1=12&ind2p2=25&ind2p3=50&ind3p1=12&ind3p2=25&ind3p3=50&pov1=mas&pov2=mas&pov3=none&pov1p1=30&pov1p2=&pov2p1=90&pov2p2=&pov3p1=&pov3p2=&newsInd=T[/img]

I will happily take a series of NR's in which all they announce is that they continue to stay on time. This AME debacle and lengthy reformulation delay has cost us investors immensely and I don't just mean in  terms of the share price and opportunity cost. I mean even looking beyond the possibility of ph 2 acute success, the immediate need for capital to fund a 2 year ph 3 is going to be enormously dilutive unless somehow they can credibly get chronic back on the table enabling a better re-rate prior to the next pp.